Literature DB >> 6890635

Effects of naloxone on d-amphetamine- and apomorphine-induced behavior.

R Hitzemann, J Curell, D Hom, H Loh.   

Abstract

The effects of acute naloxone administration on d-amphetamine- and apomorphine-induced behavior were studied. Naloxone, in doses of 0.3-10 mg/kg (s.c.), antagonized the increase in ambulation and rearing induced by 1 mg/kg of d-amphetamine. When the dose of d-amphetamine was increased to 3 mg/kg, naloxone (3 mg/kg) antagonized only the increase in rearing activity. No dose (0.3-10 mg/kg, s.c.) of naloxone significantly affected d-amphetamine- or apomorphine-induced stereotyped activity. Naloxone (3 mg/kg) significantly augmented the apomorphine (1 mg/kg, s.c.)-induced increase in ambulation but attenuated the apomorphine (0.3 mg/kg)-induced increase in rearing activity. Naloxone (3 mg/kg) or apomorphine (0.03 mg/kg) significantly decreased the ambulation and rearing induced by a novel environment. In combination and in these doses, naloxone and apomorphine produced an additive effect on these behaviors. The neurochemical mechanisms by which naloxone affects d-amphetamine- and apomorphine-induced behavior were investigated. Naloxone (10(-6) M) had no significant effect on [3H]spiroperidol binding in either the caudate nucleus or nucleus accumbens except for a modest inhibition (24%) of both the Km and Bmax in the accumbens microsomal fraction. Similarly, naloxone (10(-6) M) had no significant effect on [3H]dopamine(DA) uptake into either brain region nor did naloxone alter the d-amphetamine-inhibition of uptake. Using perfused tissue slices, naloxone (10(-6)-10(-5) M) significantly attenuated the increase in [3H]DA release induced by d-amphetamine (10(-5) M) in both brain regions. Naloxone (1 mg/kg) had no significant effect on DA or dihydroxyphenyl-acetic acid (DOPAC) levels or on the DA/DOPAC ratio in the caudate nucleus or nucleus accumbens. However, naloxone did reverse the marked increases in the DA-DOPAC ratio induced by d-amphetamine (1 mg/kg) in both brain regions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890635     DOI: 10.1016/0028-3908(82)90114-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

2.  Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.

Authors:  Megan J Moerke; Matthew L Banks; Kejun Cheng; Kenner C Rice; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2017-10-13       Impact factor: 4.492

3.  Naloxone blockade of amphetamine place preference conditioning.

Authors:  K A Trujillo; J D Belluzzi; L Stein
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Naltrexone blocks amphetamine-induced hyperactivity, but not disruption of social and agonistic behavior in mice and squirrel monkeys.

Authors:  J T Winslow; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Effects of naltrexone, and d-amphetamine, and their interaction on the stimulus control of choice behavior of rats.

Authors:  D M Grilly; G C Gowans
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Influence of naloxone upon motor activity induced by psychomotor stimulant drugs.

Authors:  D N Jones; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

7.  Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeys.

Authors:  R J Vermeulen; B Drukarch; M C Sahadat; C Goosen; A N Schoffelmeer; E C Wolters; J C Stoof
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.